Biologic rebate contracts for insulin-isophan
Original notice title
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-12 - Insulin-isophan (human)
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
40 / 100
Risk factors
No estimated contract value or framework maximum value is disclosed. Participants cannot assess potential revenue.
Open house procedure means all eligible pharmaceutical entrepreneurs can join, potentially leading to many participants...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 2 lots
- Duration until Jul 2027
- Supply of Insulin-isophan (human) pharmaceutical products
- Conclusion of discount agreements (Rabattverträge) according to §130a Abs. 8 SGB V
Show full summary
Open House procedure by Techniker Krankenkasse (TK) and other health insurers for discount agreements on Insulin-isophan (human) in two dosage forms: cylinder ampoules and pre-filled pens. The procedure is open to all eligible pharmaceutical entrepreneurs meeting specific criteria under German law. No exclusivity is guaranteed; contracts are concluded with all qualifying bidders on standard terms. The contract term is 24 months starting August 1, 2025, ending July 31, 2027. No estimated contract value is provided. Submission is possible at any time during the contract period via email (with qualified electronic signature) or post.
Risks
No estimated contract value or framework maximum value is disclosed. Participants cannot assess potential revenue.
Open house procedure means all eligible pharmaceutical entrepreneurs can join, potentially leading to many participants...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with valid marketing authorization for the product
- Registered seat in Germany, EU, or EEA
Eligibility
- No convictions or events triggering exclusion under §§123, 124 GWB within last 3-5 years
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (2)
LOT-0001
Insulin-isophan (human) - Cylinder Ampoules
Discount agreement for Insulin-isophan (human) in cylinder ampoules dosage form. Open to all eligible pharmaceutical entrepreneurs meeting the requirements of §130a Abs. 8 SGB V.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Insulin-isophan (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
Value note
Show original TED data
Original lot title
Insulin-isophan (human) (Darreichungsform: Zylinderampullen)
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Insulin-isophan (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
LOT-0002
Insulin-isophan (human) - Pre-filled Pen
Discount agreement for Insulin-isophan (human) in pre-filled pen dosage form. Open to all eligible pharmaceutical entrepreneurs meeting the requirements of §130a Abs. 8 SGB V.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Insulin-isophan (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
Value note
Show original TED data
Original lot title
Insulin-isophan (human) (Darreichungsform: Fertigpen)
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Insulin-isophan (human) [zur Aufteilung in Lose siehe bei den Angaben zu den Losen] zu schließen.
Procurement Details
- Publication date
- 11 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 298227-2025
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
40 / 100
Risk factors
No estimated contract value or framework maximum value is disclosed. Participants cannot assess potential revenue.
Open house procedure means all eligible pharmaceutical entrepreneurs can join, potentially leading to many participants...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications